Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

RUBIDIUM CHLORIDE

Reparixin, Placebo - Tablet for oral use

Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

RoActemra 162 mg solution for injection in pre-filled syringe., Humira 80 mg solution for injection in pre-filled pen

Rucaparib

SARCLISA 20mg/mL concentrate for solution for infusion.

SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

SIROLIMUS

Saruparib

Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib

Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN

Sucrose octaacetate [NF], SODIUM CHLORIDE, METHYLPREDNISOLONE VIATRIS 1 g, poudre pour solution injectable (I.V.), LIQUID PREDNISONE

TNTL capsule

TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

Talazoparib Tosylate

Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis

Trecondi 1 g powder for solution for infusion, FLUDARABINE PHOSPHATE, THIOTEPA, Trecondi 5 g powder for solution for infusion

XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

Zemplar (paricalcitol ) capsules

[18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET

volrustomig, Monalizumab

A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma

A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

Frequently asked questions